On Apr. 16, 2020, Atossa Therapeutics announced a new drug development program called COVID-19 HOPE. The program used a novel combination of two drugs that were previously approved by the FDA for other diseases.

The goal of the COVID-19 HOPE program was to develop a therapy to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators.